Short‐term effects of intravitreal bevacizumab (Avastin®) on retrobulbar hemodynamics in patients with neovascular age‐related macular degeneration

Acta Ophthalmol. 2011: 89: e41–e45

[1]  A. Mete,et al.  Effects of intravitreal bevacizumab (Avastin®) therapy on retrobulbar blood flow parameters in patients with neovascular age‐related macular degeneration , 2009, Journal of clinical ultrasound : JCU.

[2]  P. Massin,et al.  Ultrasound assessment of short‐term ocular vascular effects of intravitreal injection of bevacizumab (Avastin®) in neovascular age‐related macular degeneration , 2010, Acta ophthalmologica.

[3]  Kanji Takahashi,et al.  Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab , 2010, British Journal of Ophthalmology.

[4]  N. Bressler.  Antiangiogenic approaches to age-related macular degeneration today. , 2009, Ophthalmology.

[5]  Yuan-Chieh Lee,et al.  Acute Vision Loss after Intravitreal Injection of Bevacizumab (Avastin) Associated with Ocular Ischemic Syndrome , 2009, Ophthalmologica.

[6]  Thomas Ach,et al.  Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[7]  A. Hirata,et al.  Changes in choriocapillaris fenestration of rat eyes after intravitreal bevacizumab injection , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[8]  A. Harris,et al.  Combined treatment of intravitreal bevacizumab and intravitreal triamcinolone in patients with retinal vein occlusion: 6 months of follow-up , 2009, Graefe's Archive for Clinical and Experimental Ophthalmology.

[9]  N. Eter,et al.  Intraocular pharmacokinetics of bevacizumab after a single intravitreal injection in humans. , 2008, American journal of ophthalmology.

[10]  M. Larsen,et al.  Optical coherence tomography and vessel diameter changes after intravitreal bevacizumab in diabetic macular oedema , 2008, Acta ophthalmologica.

[11]  N. Bressler,et al.  A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. , 2007, Ophthalmology.

[12]  F. Kabbinavar,et al.  Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. , 2007, Journal of the National Cancer Institute.

[13]  P. Keegan,et al.  FDA drug approval summary: bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. , 2007, The oncologist.

[14]  A. Ho,et al.  INTRAVITREAL BEVACIZUMAB (AVASTIN) IN CENTRAL RETINAL VEIN OCCLUSION , 2006, Retina.

[15]  R. Avery,et al.  Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. , 2006, Ophthalmology.

[16]  G. Richard,et al.  Reproducibility of blood flow velocity measurements using colour decoded Doppler imaging , 2004, Eye.

[17]  H. Abalı,et al.  Bevacizumab, bleeding, thrombosis, and warfarin. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Kato,et al.  Retrobulbar circulation in patients with age-related maculopathy , 2002, Eye.

[19]  I. Zachary.  Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. , 2001, American journal of physiology. Cell physiology.

[20]  P. Heggerick,et al.  Color Doppler imaging of normal orbital vasculature. , 1995, Ophthalmology.